N-MER, INC.Option Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
BY AND AMONG HYSEQ, INC.,Agreement and Plan of Merger • November 12th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
EXHIBIT 4.9 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of November 13, 2001, among Hyseq, Inc., a Nevada corporation (the "Company"), and Affymetrix, Inc. a Delaware corporation (the...Registration Rights Agreement • April 1st, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
Hyseq, Inc. andRights Agreement • July 31st, 1998 • Hyseq Inc • In vitro & in vivo diagnostic substances • Nevada
HYSEQ, INC.Warrant Agreement • June 12th, 1997 • Hyseq Inc • New York
between HYSEQ, INC. and AFFYMETRIX, INC.Settlement Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
HYSEQ, INC. WARRANTHyseq Inc • June 14th, 2002 • In vitro & in vivo diagnostic substances
EXHIBIT 10.7 HYSEQ, INC.Stock Purchase Agreement • June 12th, 1997 • Hyseq Inc • California
HYSEQ, INC.Registration Rights Agreement • June 12th, 1997 • Hyseq Inc • Illinois
EXHIBIT 4.7 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of April 5, 2002, by and among Hyseq, Inc., a Nevada corporation (the "Company"), and the investors signatory hereto (each a...Registration Rights Agreement • June 14th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
HYSEQ, INC.Underwriting Agreement • July 17th, 1997 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4.6 RIGHTS AGREEMENT AMENDMENT This Amendment, dated as of November 9, 2002, to the Rights Agreement, dated as of June 5, 1998 (the "Rights Agreement"), is between Hyseq, Inc., a Nevada corporation (the "Company"), and U.S. Stock Transfer...Rights Agreement • November 27th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
ARCA BIOPHARMA, INC., Issuer AND [TRUSTEE], Trustee FORM OF INDENTURE Dated as of [—], 20 Subordinated Debt SecuritiesIndenture • March 9th, 2011 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
ARTICLE I. DEFINITIONSSecurities Purchase Agreement • June 14th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • May 7th, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
ARCA biopharma, Inc.ARCA Biopharma, Inc. • July 22nd, 2020 • In vitro & in vivo diagnostic substances • New York
ARCA biopharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
ARTICLE I DEFINITIONSSecurities Purchase Agreement • September 25th, 2001 • Hyseq Inc • In vitro & in vivo diagnostic substances • New York
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Common Stock Warrant Agreement • April 25th, 2017 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
NUVELO, INC. INDENTURENuvelo Inc • July 8th, 2003 • In vitro & in vivo diagnostic substances • New York
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • May 7th, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 23rd, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January , 2013, is by and among ARCA biopharma, Inc., a Delaware corporation (the “Company”), and the undersigned buyer ( “Buyer”).
EXHIBIT 10.29 WARRANT PURCHASE AGREEMENT This Warrant Purchase Agreement (the "Agreement") is made as of January 8, 2002 by and between Hyseq, Inc., a Nevada corporation (the "Company"), and Amgen Inc., a Delaware corporation ("Purchaser"). The...Warrant Purchase Agreement • May 15th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
HYSEQ INC. HYSEQ, INC. STOCK OPTION AGREEMENT ----------------------Hyseq Inc • May 20th, 1998 • In vitro & in vivo diagnostic substances • California
ARCA BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Preferred Stock Warrant Agreement • April 25th, 2017 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
Exhibit 99.1 VOTING AGREEMENT VOTING AGREEMENT (the "Agreement"), dated as of November 9, 2002, between the undersigned stockholder ("Stockholder") of Hyseq, Inc., a Nevada corporation ("Parent"), and Variagenics, Inc., a Delaware corporation (the...Voting Agreement • November 12th, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • Delaware
ARTICLE 1. DEFINITIONS -----------Patent License Agreement • August 7th, 1997 • Hyseq Inc • In vitro & in vivo diagnostic substances • Illinois
ARCA BIOPHARMA, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20Debt Securities Warrant Agreement • April 25th, 2017 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
This DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between ARCA BIOPHARMA, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
EXHIBIT 10.3(a) EMPLOYMENT AGREEMENT -------------------- THIS EMPLOYMENT AGREEMENT ("Agreement"), made and entered into as of the 1st day of August, 1994, by and between HYSEQ, INC., a Nevada corporation (the "Corporation"), and DR. RADOJE T. DRMANAC...Employment Agreement • June 12th, 1997 • Hyseq Inc • Illinois
UNDERWRITING AGREEMENT DATED FEBRUARY 1, 2005 NUVELO, INC. 8,500,000 Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2005 • Nuvelo Inc • In vitro & in vivo diagnostic substances • New York
Nuvelo, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 8,500,000 shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 1,275,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
RECITALSCollaboration and License Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
PLACEMENT AGENCY AGREEMENT January 21, 2014Placement Agency Agreement • February 4th, 2014 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
Introduction. Subject to the terms and conditions herein (this “Agreement”), ARCA biopharma, Inc., a Delaware corporation (the “Company”), proposes to offer and sell registered securities of the Company, including, but not limited to, shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and registered warrants to purchase Common Stock (the “Warrants” and, together with the Shares, and the Common Stock underlying the Warrants, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”) through Dawson James Securities, Inc., as placement agent (“Dawson” or the “Placement Agent”).
AMGEN INC. AND HYSEQ, INC.License Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934,...Joint Filing Agreement • February 14th, 2007 • Nuvelo Inc • In vitro & in vivo diagnostic substances
The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
ContractARCA Biopharma, Inc. • March 27th, 2009 • In vitro & in vivo diagnostic substances • Delaware
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
NUVELO, INC. INDENTURENuvelo Inc • July 8th, 2003 • In vitro & in vivo diagnostic substances • New York
